<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4AAE76DE-5807-40EF-B3FE-824A330ECEF3"><gtr:id>4AAE76DE-5807-40EF-B3FE-824A330ECEF3</gtr:id><gtr:name>South Tees Hospitals NHS Foundtn Trust</gtr:name><gtr:address><gtr:line1>James Cook Hospital</gtr:line1><gtr:line2>Marton Road</gtr:line2><gtr:postCode>TS4 3BW</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DE96B8F6-2787-48DA-B0DB-7935BEDF92BA"><gtr:id>DE96B8F6-2787-48DA-B0DB-7935BEDF92BA</gtr:id><gtr:name>Gemini Biosciences Ltd.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9BA09FE7-12AE-457B-8510-0D7FEE969145"><gtr:id>9BA09FE7-12AE-457B-8510-0D7FEE969145</gtr:id><gtr:name>Yorclinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BA3C264-769F-487E-B61A-2D4CB6A105B6"><gtr:id>8BA3C264-769F-487E-B61A-2D4CB6A105B6</gtr:id><gtr:name>University of the Highlands and Islands</gtr:name><gtr:address><gtr:line1>Executive Office</gtr:line1><gtr:line2>Ness Walk</gtr:line2><gtr:line4>Inverness</gtr:line4><gtr:postCode>IV3 5SQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3BC3006B-3146-4485-A4BB-10B39F60FB4A"><gtr:id>3BC3006B-3146-4485-A4BB-10B39F60FB4A</gtr:id><gtr:name>Mesoscale Diagnostics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE"><gtr:id>70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE</gtr:id><gtr:name>North Middlesex University Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E6EDF4EA-88D6-4C1C-94DE-8DCC2651074D"><gtr:id>E6EDF4EA-88D6-4C1C-94DE-8DCC2651074D</gtr:id><gtr:name>Healx Ltd</gtr:name><gtr:address><gtr:line1>St John's Innovation Centre</gtr:line1><gtr:line2>Cowley Road</gtr:line2><gtr:postCode>CB4 0WS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F6A0EE8E-947D-446A-A17D-A5772EBD4D91"><gtr:id>F6A0EE8E-947D-446A-A17D-A5772EBD4D91</gtr:id><gtr:name>Western General Hospital</gtr:name><gtr:address><gtr:line1>Crewe Road South</gtr:line1><gtr:postCode>EH4 2XU</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4AAE76DE-5807-40EF-B3FE-824A330ECEF3"><gtr:id>4AAE76DE-5807-40EF-B3FE-824A330ECEF3</gtr:id><gtr:name>South Tees Hospitals NHS Foundtn Trust</gtr:name><gtr:address><gtr:line1>James Cook Hospital</gtr:line1><gtr:line2>Marton Road</gtr:line2><gtr:postCode>TS4 3BW</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DE96B8F6-2787-48DA-B0DB-7935BEDF92BA"><gtr:id>DE96B8F6-2787-48DA-B0DB-7935BEDF92BA</gtr:id><gtr:name>Gemini Biosciences Ltd.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9BA09FE7-12AE-457B-8510-0D7FEE969145"><gtr:id>9BA09FE7-12AE-457B-8510-0D7FEE969145</gtr:id><gtr:name>Yorclinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BA3C264-769F-487E-B61A-2D4CB6A105B6"><gtr:id>8BA3C264-769F-487E-B61A-2D4CB6A105B6</gtr:id><gtr:name>University of the Highlands and Islands</gtr:name><gtr:address><gtr:line1>Executive Office</gtr:line1><gtr:line2>Ness Walk</gtr:line2><gtr:line4>Inverness</gtr:line4><gtr:postCode>IV3 5SQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3BC3006B-3146-4485-A4BB-10B39F60FB4A"><gtr:id>3BC3006B-3146-4485-A4BB-10B39F60FB4A</gtr:id><gtr:name>Mesoscale Diagnostics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE"><gtr:id>70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE</gtr:id><gtr:name>North Middlesex University Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E6EDF4EA-88D6-4C1C-94DE-8DCC2651074D"><gtr:id>E6EDF4EA-88D6-4C1C-94DE-8DCC2651074D</gtr:id><gtr:name>Healx Ltd</gtr:name><gtr:address><gtr:line1>St John's Innovation Centre</gtr:line1><gtr:line2>Cowley Road</gtr:line2><gtr:postCode>CB4 0WS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F6A0EE8E-947D-446A-A17D-A5772EBD4D91"><gtr:id>F6A0EE8E-947D-446A-A17D-A5772EBD4D91</gtr:id><gtr:name>Western General Hospital</gtr:name><gtr:address><gtr:line1>Crewe Road South</gtr:line1><gtr:postCode>EH4 2XU</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12035"><gtr:id>97CFD87E-D37A-49DE-9512-63F045B2D6FA</gtr:id><gtr:title>TAILoR (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a Strategy for the Reduction of Insulin Resistance in HIV-Positive Individuals on Combination Antiretroviral Therapy (cART)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12035</gtr:grantReference><gtr:abstractText>HIV is now a chronic disease treatable by combination antiretroviral therapy (cART). This has resulted in a reduction in HIV-related mortality, but has also led to the emergence of serious adverse effects such as HIV lipodystrophy (HIVLD). This condition is characterised by fat loss (from face and limbs) and fat accumulation (abdomen and back of neck), high cholesterol levels, reduced response to insulin (insulin resistance) and sometimes diabetes, and importantly, an increase in the risk of ischaemic heart disease. A key abnormality seems to be insulin resistance, which can also occur in untreated HIV patients. Although more ?lipid-friendly? anti-HIV drugs have been introduced, because (a) drugs have to be used in combinations, (b) there is frequent switching of drugs because of other side effects or the occurrence of viral mutations, and (c) we are treating an increasingly older HIV-positive population, almost all patients will develop insulin resistance. There is a need to find new strategies to reduce insulin resistance in HIV-positive individuals treated with cART, which ultimately will reduce the associated cardiovascular risk. We will use telmisartan, a drug that is widely used for the treatment of hypertension. In hypertensive patients, it has been shown to reduce insulin resistance and improve various indicators (biomarkers) of cardiovascular health. In HIVLD, the fat cell (adipocyte) is key to the development of insulin resistance. Anti-HIV drugs interact with fat cells, making them lose their ability to store fat in some instances, and increase the secretion of active molecules called cytokines, which lead to inflammation and insulin resistance. We have shown that telmisartan can prevent HIV drug-induced fat loss in adipocytes, reduction in adiponectin (a marker of cardiac health) and lipin1 (a marker of fat cell formation). The aim of the proposed trial is to investigate whether telmisartan can reduce the insulin resistance observed in HIV-positive individuals on cART. We will compare 3 different doses of telmisartan with the control group (those who do not take telmisartan) to determine the effect on insulin resistance over a period of 48 weeks. We are using a novel adaptive trial design for this study ? this has been developed in conjunction with the North West MRC trials methodology hub. Our team consists of experts in HIV medicine, pharmacology and diabetes, scientists and trial statisticians to ensure the successful conduct of this trial, which will be run via an accredited clinical trials unit. We have provided full justification for costs requested. If telmisartan shows a significant beneficial effect on insulin resistance, the next step would be to conduct a larger phase III study to assess its effect on cardiovascular morbidity in HIV-positive individuals treated with cART.</gtr:abstractText><gtr:technicalSummary>Research design: A Phase II randomised, open labelled, dose ranging trial of telmisartan in HIV-positive individuals on cART over a period of 48 weeks. An adaptive trial design will be utilised with a single interim analysis performed when half of the planned maximum of 336 patients have been followed up for at least 24 weeks. Study population: Adult HIV-positive individuals receiving antiretroviral therapy containing a boosted protease inhibitor [Lopinavir/ritonavir (LPV/r), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Fosamprenavir/ritonavir (FPV/r)] and/or Efavirenz (EFV), for at least 6 months. Exclusion criteria include known diabetes, low blood pressure, suspected poor compliance, renal disease, use of unboosted ATV and use of ACE-inhibitors. Patient recruitment and interventions: Patients will be recruited from 8 HIV treatment centres and initially randomised (1:1:1:1 allocation ratio) to receive 3 doses of telmisartan (20, 40, and 80mg) or no intervention (controls). In the telmisartan 40 and 80mg arms, dose titration will be undertaken over 4 weeks in order to step-up to the allocated dose, or else the maximum tolerated dose if the target is not achieved. Proposed outcome measures: The primary outcome measure is the change in insulin resistance in the telmisartan-treated group(s) in comparison with the control group as measured by HOMA-IR at 24 weeks. Secondary outcomes include (a) change in visceral fat accumulation; and (b) change in the expression of biomarkers (fasting lipids, adiponectin, lipin1, IL-6, resistin, TNFa and hs-CRP) in telmisartan treated group(s) in comparison to the controls. MRI scans and MR spectroscopy will also be performed at baseline and at 24 weeks in a sub-set of patients. These measurements represent the mechanistic assessment of drug action. Assessments &amp;amp; follow up: Fasting blood glucose and insulin (for calculating HOMA-IR) and lipid assessments will be performed at baseline, 12, 24 and 48 weeks. An independent Data Monitoring and Ethics Committee will monitor study progress and patient safety. Proposed sample size: The maximum total sample size will be 336 patients across all treatment arms and the study will seek to recruit 34 additional patients to account for a 10% drop-out rate. This calculation is based on a one-sided type I error of 5% and a power of 90% of achieving significance if patients on telmisartan have a 65% chance of observing a greater reduction in HOMA-IR score than the controls. Statistical analysis: When 24 week data are available on 168 patients (42 per group), an interim analysis will be conducted. If any active dose can already be seen to be substantially better than control in terms of HOMA-IR, then the trial will be stopped and that dose recommended for further study. Otherwise, recruitment will continue to control and to any active doses that are better than control in terms of HOMA-IR until another 42 patients have been observed in each remaining treatment arm. Project time tables including recruitment rate: Trial duration is 47 months; m1-4, trial set up; m5-30, recruitment; m25, interim analysis; m31-42, follow-up; m43-47, final data cleaning and analysis. The 25 month recruitment period is based on 8 HIV treatment centres each recruiting 3 patients per month with a 4 month staggered start.</gtr:technicalSummary><gtr:fund><gtr:end>2016-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>615661</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TAILoR - Royal Liverpool Hospital</gtr:description><gtr:id>FCAC6A9B-166F-4637-84F7-21433F7B0514</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>nCCKuFS1Ws5-1</gtr:outcomeId><gtr:partnerContribution>Cosponsoring the trial and patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Middlesex University Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infectious Diseases</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>B9E01DA6-2C58-4754-AC4B-0862FE1E3D2A</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-12</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Healx Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration in Drug repositioning</gtr:description><gtr:id>9068C5C1-F7F1-4ACE-81EA-2155428EB77B</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>56c4a4a2d3b344.40253286-1</gtr:outcomeId><gtr:partnerContribution>The collaborator will provide their expertise in computational approaches for drug repositioning which will be undertaken as part of this collaboration.</gtr:partnerContribution><gtr:piContribution>Sudeep Pushpakom entered into a collaboration with this partner.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brighton and Sussex University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Infectious Diseases Service (CIS)</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>86B720EA-2D7D-479E-9848-878E222131C5</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-8</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yorclinic</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>F0B5A0DC-EBF7-4200-B331-7A5ED84B006A</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-9</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infectious Diseases</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>C83A6B0D-7216-4BA5-89D1-9706471863EB</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-1</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southmead Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>D34204A9-4AC9-4343-BE4D-870CAF4D4E2D</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-11</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infectious Diseases</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>34EAEDBA-F26B-4E31-8A7B-147F570125BC</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-2</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St James's University Hospital (Jimmy's)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infectious Diseases</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>F63A1FC7-9FCD-4CDD-8E32-2725E88487AB</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-5</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mesoscale Diagnostics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Biomarker analysis collaboration with MesoScale Discovery</gtr:description><gtr:id>BF0BBC6E-FFD1-4A98-943B-1E0F392D1436</gtr:id><gtr:impact>No outputs yet.</gtr:impact><gtr:outcomeId>56c499af9ec703.51827881-1</gtr:outcomeId><gtr:partnerContribution>The collaborators will provide us with thier expertise in biomarker analysis and work with us in optimising protocols.</gtr:partnerContribution><gtr:piContribution>I have negotiated this collaboration to undertake analysis of biomarkers using samples from this trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infectious Diseases</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>54D687BB-E3F1-4B7C-80E5-8B733DA8DA16</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-4</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Western General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>B931457C-AC0C-4901-9E9E-9E32AB409EF7</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-6</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UHI Millennium Institute (University of the Highlands and Islands)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lipidomics collaboration (UHI)</gtr:description><gtr:id>81387B75-46B4-4099-8F6D-1B24096BF7D7</gtr:id><gtr:impact>Only output from this collaboration is some pilot data which we are working on.</gtr:impact><gtr:outcomeId>56c49bcb623ac8.07168479-1</gtr:outcomeId><gtr:partnerContribution>The collaborator has carried out some pilot lipidomic analysis for us in kind. We intend to work with them further over the coming months to generate more results and collaborate with them on grants and publications.</gtr:partnerContribution><gtr:piContribution>I have initiated this collaboration with this partner.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancaster University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Mathematics and Statistics</gtr:department><gtr:description>Lancaster University</gtr:description><gtr:id>21B6A62C-66F0-4769-A5F8-40CB1DA6864F</gtr:id><gtr:impact>The collaboration has already contributed to the preparation of TAILoR grant proposal. Further outputs are expected during analysis.</gtr:impact><gtr:outcomeId>hgmA7yhW83Y-1</gtr:outcomeId><gtr:partnerContribution>Interim analysis of the data</gtr:partnerContribution><gtr:piContribution>Coordination and conduct of trial, sample storage and analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemini Biosciences Ltd.</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with SME to utilise proteomics for drug repurposing</gtr:description><gtr:id>EF5F7732-6C74-4CB7-A871-2EDD297F9347</gtr:id><gtr:impact>No outputs yet to report</gtr:impact><gtr:outcomeId>58b9b4ee851831.31743903-1</gtr:outcomeId><gtr:partnerContribution>The industrial partner will provide part of the costs for undertaking quantitative proteomics and also waive the cost of staff time.</gtr:partnerContribution><gtr:piContribution>Sudeep Pushpakom entered into a collaboration with this Drug repurposing SME and the project is currently underway.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infectious Diseases</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>649B1B7C-EFF6-4AF9-B2C9-C34FF6C130D2</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-3</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>James Cook University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>2F583B85-6EB8-4D61-BAD4-54EB5D0CE030</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-10</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infectious Diseases</gtr:department><gtr:description>TAILoR NHS Trusts</gtr:description><gtr:id>F9DE85E9-68C5-4926-ADC9-A629C5EC2D23</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>rRXfoF1EiPF-7</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Coordinating and conducting the trial, sample storage and analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival 7th July 2014 (BPS PERSONALISED MEDICINE )</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4F564C1F-86B3-4368-BD02-133F296AA71C</gtr:id><gtr:impact>Present a broad range of science and scientific issues in an exciting and engaging environment.

To present a broad range of science and scientific issues in an exciting and engaging environment t encourge people to pursue careers in science and bring to life</gtr:impact><gtr:outcomeId>54535536d28b79.93423798</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC CDSS Drug Repositioning Workshop (Sudeep Pushpakom)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CE9AC195-27D2-480A-9D82-A6CD10318BD8</gtr:id><gtr:impact>This was a workshop organised at the University of Liverpool under the Centre for Drug Safety Science attended by scientists, academia, pharma industry and regulatory agency representatives where the current status of drug repositioning was discussed.</gtr:impact><gtr:outcomeId>56c49ea98f8922.31938583</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personalised Medicine Workshop 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C04EB0B3-B646-4470-8C26-1D70845EC887</gtr:id><gtr:impact>Inited talk at a University workshop on personalised medicine

Well apreciated</gtr:impact><gtr:outcomeId>Lox6r3jv12R</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>8300</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KE Voucher (awarded to Sudeep Pushpakom)</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>University of Liverpool</gtr:fundingOrg><gtr:id>2F444615-31B7-42EE-8160-08EB89A9BD47</gtr:id><gtr:outcomeId>56c4a53c000f35.31167713</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Liverpool Technology Directorate Voucher (awarded to Sudeep Pushpakom)</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>University of Liverpool</gtr:fundingOrg><gtr:id>B9A008F2-1589-4317-B948-77F52C0AC51E</gtr:id><gtr:outcomeId>ZLJfGLZE8sX</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Proximity to Discovery award to Sudeep Pushpakom</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>13134AEF-31F6-4A50-A54E-50D00D83594F</gtr:id><gtr:outcomeId>58b9b5d4c7ccc9.45012786</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21775</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy and Mechanism Evaluation - Supplementary funding</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>C5324641-ED11-4DCD-AEE9-AD1153893477</gtr:id><gtr:outcomeId>58b9b6e0b03b78.99601148</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1A84469F-F41F-46B8-85BD-47F5201F78E6</gtr:id><gtr:title>Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5624e74948be84.50514683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1052574D-6FC0-4012-ADF2-183FC118EFE9</gtr:id><gtr:title>Some recommendations for multi-arm multi-stage trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>pm_12583_23_23242385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D27A31B2-ACD7-4D2F-90AF-F521686A8A1D</gtr:id><gtr:title>Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.</gtr:title><gtr:parentPublicationTitle>Diabetes &amp; vascular disease research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1479-1641</gtr:issn><gtr:outcomeId>5a980515014ac4.96751279</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12035</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>